What does this research mean for the field?

While antioxidants show inconclusive clinical efficacy, dexrazoxane and standard heart failure medications effectively reduce anthracycline-induced cardiotoxicity, with statins, ranolazine, and everolimus emerging as potential cardioprotective candidates. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to understand anthracycline-induced cardiotoxicity and identify cardioprotective drugs.

January 31, 2025YAKUGAKU ZASSHIOpen Access

Anthracycline-Induced Cardiotoxicity and Exploration of Cardioprotective Drugs

Q: What is the clinical evidence from this study?

Study design: Review. Population: Anthracycline-induced cardiotoxicity. Intervention: Cardioprotective drugs.

View Full Paper

Ask AI

Bookmark

Key result

Dexrazoxane, standard HF meds, statins, and ranolazine reduce anthracycline-induced cardiotoxicity.

Why the study?

Anthracyclines pose a risk of cardiotoxicity that can impair prognosis and disrupt cancer chemotherapy, highlighting the need to understand underlying mechanisms and cardioprotective strategies.

Design

Review

Authors

AHAkiyoshi HaraTohoku Medical and Pharmaceutical University

Discussion

Member takes

Implication

Supports onco-cardiology integration for anticancer cardiotoxicity; leaves open optimal prevention protocols pending prospective trials.

Key Points

The aim is to understand anthracycline-induced cardiotoxicity and identify cardioprotective drugs.
Examined mechanisms of anthracycline cardiotoxicity focused on oxidative stress and apoptosis.
Reviewed pharmacological agents for heart protection, including both clinical and animal studies.
Discussed efficacy of various candidates such as dexrazoxane, beta-blockers, and everolimus.
Dexrazoxane and standard heart failure medications significantly reduced anthracycline-induced cardiotoxicity in humans (specific metrics not stated).
Antioxidants like resveratrol and vitamin E showed promise in animal models but unclear clinical effectiveness.
In vitro studies indicate everolimus may protect cardiomyocytes from toxicity without impairing anticancer efficacy.

PICO

Population

Anthracycline-induced cardiotoxicity

Intervention / Comparator

Cardioprotective drugs

This review provides a comprehensive overview of the mechanisms underlying anthracycline-induced cardiotoxicity and evaluates current and emerging pharmacological strategies for cardioprotection in the growing field of cardio-oncology.

Limitations

Clinical effectiveness of various antioxidant agents remains inconclusive.
Further clinical research is warranted to validate the potential of everolimus as a cardioprotective strategy.

Cite This Study

Akiyoshi Hara (2025) conducted a review in Anthracycline-induced cardiotoxicity. Cardioprotective drugs was evaluated. Dexrazoxane, standard heart failure medications, statins, ranolazine, and potentially everolimus demonstrate efficacy in reducing anthracycline-induced cardiotoxicity.

synapsesocial.com/papers/6a5e481dcf7c9f6d12e28816 https://doi.org/10.1248/yakushi.24-00185

Topics

Heart failure Statin therapy HFrEF treatment Cardio-oncology

View Full Paper

Ask AI

Bookmark

Anthracycline-Induced Cardiotoxicity and Exploration of Cardioprotective Drugs

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Topics

Anthracycline-Induced Cardiotoxicity and Exploration of Cardioprotective Drugs

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider